Two Sigma Investments LP Sells 1,042,421 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Two Sigma Investments LP lessened its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) by 29.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,548,954 shares of the biotechnology company’s stock after selling 1,042,421 shares during the period. Two Sigma Investments LP owned about 1.08% of ADMA Biologics worth $43,715,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Mark Sheptoff Financial Planning LLC acquired a new stake in shares of ADMA Biologics in the 4th quarter valued at approximately $35,000. Vision Financial Markets LLC acquired a new stake in ADMA Biologics in the fourth quarter valued at approximately $51,000. AlphaQuest LLC acquired a new stake in ADMA Biologics in the fourth quarter valued at approximately $84,000. CIBC Private Wealth Group LLC grew its stake in shares of ADMA Biologics by 137.1% during the fourth quarter. CIBC Private Wealth Group LLC now owns 5,108 shares of the biotechnology company’s stock worth $95,000 after buying an additional 2,954 shares during the last quarter. Finally, Jones Financial Companies Lllp increased its holdings in shares of ADMA Biologics by 303.4% during the fourth quarter. Jones Financial Companies Lllp now owns 5,733 shares of the biotechnology company’s stock worth $98,000 after buying an additional 4,312 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Raymond James raised their price objective on ADMA Biologics from $25.00 to $32.00 and gave the company a “strong-buy” rating in a report on Thursday, May 8th. StockNews.com downgraded ADMA Biologics from a “hold” rating to a “sell” rating in a research report on Friday, May 9th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 price target on shares of ADMA Biologics in a research note on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, ADMA Biologics presently has a consensus rating of “Moderate Buy” and an average price target of $24.25.

ADMA Biologics Price Performance

ADMA stock opened at $20.44 on Wednesday. The company has a market capitalization of $4.88 billion, a P/E ratio of 73.00 and a beta of 0.57. The company has a fifty day moving average price of $20.52 and a 200-day moving average price of $18.88. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics, Inc. has a 52-week low of $9.31 and a 52-week high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.02). The company had revenue of $114.80 million during the quarter, compared to analyst estimates of $116.40 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The business’s revenue for the quarter was up 40.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.08 earnings per share. As a group, equities analysts expect that ADMA Biologics, Inc. will post 0.51 EPS for the current year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.